<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="493">
  <stage>Registered</stage>
  <submitdate>9/09/2005</submitdate>
  <approvaldate>15/09/2005</approvaldate>
  <actrnumber>ACTRN12605000413628</actrnumber>
  <trial_identification>
    <studytitle>A preliminary safety study comparing the concentration of a local anaesthetic absorbed into the blood (when trickling near the surgical site for 96hours after surgery) to published threshold for toxicity</studytitle>
    <scientifictitle>Pilot study investigating the safety &amp; efficacy of 96hr duration local anaesthesia (ropivacaine) infused at the incision site for post-operative pain management following right hemicolectomy</scientifictitle>
    <utrn />
    <trialacronym />
  </trial_identification>
  <conditions>
    <healthcondition>Bowel Cancer Surgery</healthcondition>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Bowel - Anal</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Bowel - Back passage (rectum) or large bowel (colon)</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Bowel - Small bowel (duodenum and ileum</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Anaesthesiology</conditioncode1>
      <conditioncode2>Pain management</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Surgery</conditioncode1>
      <conditioncode2>Other surgery</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Pain management with local anaesthetic (ropivacaine) continuous infusion during- &amp; post-op using ON-Q pain Buster device.</interventions>
    <comparator>there was no control arm in this pilot study</comparator>
    <control>Uncontrolled</control>
    <interventioncode>Treatment: Devices</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Safety of LA</outcome>
      <timepoint>serial blood sampling 0-96hr of local anaesthetic administration</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Efficacy (measured by 12hrly pain scores using Visual Analogue Scales; and also by frequency of using Patient Controlled Analgesia with narcotic).</outcome>
      <timepoint>Over the 4-5 days of the admission.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Infection rate (scored by the appearance, duration, organism, and treatment of infection at the surgical site).</outcome>
      <timepoint>During the 4-day treatment with the PainBuster.</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Able to give informed consent. ASA Score &lt;4 (ie., level 1, 2 or 3). Normal to mildly elevated biochemical indices of renal and/or hepatic functionMental status of the patient should be considered and included only if in the opinion of the surgeon and other attended medical staff, that the patient is capable of giving informed consent and would be capable of complying with the reasonable instructions to allow the study to progressSmokers are admissible, and other drugs/medicines normally taken, other than those specified below. Patient with no previous abdominal surgery.</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>0</inclusivemaxage>
    <inclusivemaxagetype>Not stated</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Failure to provide written informed consentUnder 18 years of agePregnancy. Clearly pregnant females with bowel cancer would be a complication requiring specific clinical management, and so not appropriate for this pilot studyASA Score &gt;4 (ie., level 4, 5)Moderate to severely elevated indices of renal and/or hepatic function, and patients with dementiaTaking drugs known to influence ropivacaine kinetics (CYP1A2 or CYP3A inhibitor/inducers; fluvoxamine, quinoline antibacterials, conazole antifungals)Taking drugs that may affect pain perception [narcotics (including codeine containing preparations), tricyclic antidepressants, regular non-steroidal use including COX-2 inhibitors, chronic pain killers, anti-epileptic drugs also used in pain therapy)Larger tumor size (&gt;8cm)Previous abdominal surgery, including laparotomyKnown allergy to ropivacaine or fentanyl.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Non-randomised trial</allocation>
    <concealment />
    <sequence />
    <masking>Open (masking not used)</masking>
    <assignment>Single group</assignment>
    <designfeatures />
    <endpoint>Safety</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 3 / Phase 4</phase>
    <anticipatedstartdate>2/01/2005</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>10</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Completed</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
  </recruitment>
  <sponsorship>
    <primarysponsortype>Charities/Societies/Foundations</primarysponsortype>
    <primarysponsorname>TQEH Research Foundation</primarysponsorname>
    <primarysponsoraddress>50 Woodville Rd
Woodville SA 5011</primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Commercial sector/Industry</fundingtype>
      <fundingname>untied supporting grant from Astra Zeneca Pharmaceuticals (Australia)</fundingname>
      <fundingaddress>Astra Zeneca
P.O. Box 131
North Ryde NSW 1670</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <fundingsource>
      <fundingtype>Charities/Societies/Foundations</fundingtype>
      <fundingname>TQEHRF</fundingname>
      <fundingaddress>50 Woodville Rd
Woodville SA 5011</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>Commercial sector/Industry</sponsortype>
      <sponsorname>Astra Zeneca</sponsorname>
      <sponsoraddress>P.O. Box 131
North Ryde NSW 1670</sponsoraddress>
      <sponsorcountry>Australia</sponsorcountry>
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>This is a pilot study to consider whether post-operative pain management (following right hemicolectomy surgery using a lateral transverse incision) with continuous ropivacaine infusion using an elastomeric infusion pump (ON-Q PainbusterÃ¿Â¿??Ã¿Â¿?Ã¿Â¿Ã¿Â®) for 96hr (rather than epidural) is safe, based on the margin between steady-state plasma ropivacaine concentrations attained (in particular, the unbound concentrations) and the systemic toxicity threshold(s). Whilst this device and local anaesthetic approach are currently used for post-op pain management, common usage in Australia is currently limited to 48-hr post-op.</summary>
    <trialwebsite />
    <publication>119.	Corso OH, Karatassas A, Hewett PJ, Morris RG. Pilot study examining safety of extended ropivacaine infusion into the incision-site following right hemicolectomy. Proc Aust Soc Clin Exp Pharmacol Toxicol, 11:1-24. 2005
112.	Corso OH, Morris RG, Hewett PJ, Karatassas A. Safety of 96-hour incision-site continuous infusion of ropivacaine for post-operative analgesia following bowel-cancer resection. Ther Drug Monit 29:57-63. 2007</publication>
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>The Queen Elizabeth Hospital</ethicname>
      <ethicaddress>28 Woodville Rd
Woodville SA 5011</ethicaddress>
      <ethicapprovaldate>13/01/2005</ethicapprovaldate>
      <hrec>2004142</hrec>
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Associate Professor Ray Morris</name>
      <address>Clinical Pharmacology
The Queen Elizabeth Hospital
28 Woodville Rd
Woodville SA 5011</address>
      <phone>+61 8 82226753</phone>
      <fax>+61 8 82226033</fax>
      <email>ray.morris@nwahs.sa.gov.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Mr Peter Hewett</name>
      <address>Department of Surgery
The Queen Elizabeth Hospital
28 Woodville Rd
Woodville SA 5011</address>
      <phone>+61 8 82226284</phone>
      <fax>+61 8 82226033</fax>
      <email>ray.morris@nwahs.sa.gov.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>